Mick Ruxin, M.D.
President, Chief Executive Officer and Director
Dr. Ruxin has been a strategic advisor to the Company since December 2017. Previously, Dr. Ruxin was the Chairman, CEO and Founder of Global Med Technologies, Inc. (GLOB). He grew GLOB from a foundational concept to an international medical software company, specializing in FDA approved software, with specific diagnostic capabilities, and serving over 30 countries on 4 continents. Under his leadership, GLOB had its initial financing, its public offering and subsequent follow-on financings. Dr. Ruxin also founded PeopleMed, Inc., a validation and chronic disease management software subsidiary of GLOB. In addition, he conceived and executed the acquisition and financing of Inlog, a French software company serving the EU, becoming the Directeur General and responsible for European Operations, and eDonor, a US based regulated software company serving domestic and international blood donor centers. Prior to Dr. Ruxin engineering the sale of GLOB to a NYSE company, Haemonetics Corp. (HAE), he led his team to national prominence by being awarded the #1 position in quality of product and customer service against billion dollar software companies, rated by an industry-respected, independent software rating service. After GLOB's acquisition by Haemonetics, Dr. Ruxin was asked to stay with the company through the transition. Dr. Ruxin was on the Executive Management Team (EMT) at Haemonetics for approximately 6 months after the merger. The EMT was responsible for diagnostic strategies and identified domestic and international software opportunities for the Company. Before founding Global Med Technologies, Dr. Ruxin founded and was President and CEO of DataMed International, Inc. (DMI), a private, international drugs of abuse management company (from 1989-1997). DMI's clients included FedEx, International Multi-Foods, Los Alamos National Laboratories, Chevron, ConAgra, Nestles and AT&T, among over 500 other companies. Dr. Ruxin was one of the first 10 certified Medical Review Officers in the country, and he participated in writing the Federal legislation for drugs of abuse testing. Dr. Ruxin received his M.D. degree from the University of Southern California and his B.A degree in Philosophy from the University of Pittsburgh.
Senior Director, Business Development
Trevor presently serves as the Senior Director of Business Development for Avant Diagnostics. He has 20+ years of cancer leadership experience working in the field of enabling technologies for cancer care and is excited to now be leading the charge for Avant Diagnostics in proteomic-based, personalized medicine that empowers oncologists, cancer patients and their families.
Prior to Avant Diagnostics, Trevor worked in various capacities with Elekta Inc., a global provider of medical devices for the treatment of cancer and brain disorders, culminating in his appointment as Senior Director of Elekta Canada. In this role, he was responsible for all of Elekta’s Business Development in Canada.
Prior to his work with Elekta, Trevor was the Senior Vice President of Sales and Marketing at OpTx Corporation, a company that created the world’s first oncology-specific electronic medical record and decision support system. He helped develop the company into an international healthcare services and technology company before its eventual sale to Varian Medical Systems, itself a leading supplier of medical devices for radiation therapy in the oncology community.
Prior to OpTx, Trevor was a Sales Executive with IBM holding various leadership positions from 1984 through 1996.
Acting Chief Financial Officer
Mr. VanderMeer has been the founder and Managing Partner of Infusion 51a, LP which is a fund that restructures companies with impediments, CFO of VC firm International Infusion LP, and CFO, Founder, and Director of Vivacitas Oncology Inc. an oncology therapeutic company since December 2014, February 2014 and August 2015, respectively. Mr. VanderMeer has been instrumental in the development and expansion of International Infusion's current portfolio, leveraging key business development relationships, both domestic and international. Mr. VanderMeer has managed the firm's research committee, focusing on vetting potential projects across an array of sectors. Mr. VanderMeer is responsible for activities at each of these entities as they relate to finance, accounting, bookkeeping, working with administrators, corporate communication, and working through audits to completion. Mr. VanderMeer graduated from the University of Illinois at Chicago with a B.S. in Business Marketing and an M.B.A with a concentration in Real Estate.
Consultants to the Management Team
Lance Liotta, M.D., Ph.D.
Medical Advisory Board Chairman
Dr. Lance Liotta has served as Co-Director and Co-Founder of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University since 2005. Prior to this appointment, Dr. Liotta served as Chief of the Laboratory of Pathology, NCI, Deputy Director of NIH, Co-Director of the NCI/FDA Clinical Proteomics Program, and Director of the Anatomic Pathology Residency Program. At the NIH he went on to investigate the process of tumor invasion and metastasis at the molecular level (MMP2, and TIMP2). He was the first to describe tumor cell invasion of the basement membrane (3-step hypothesis) and the role of tumor cell pseudopodia in tumor cell invasion. Dr. Liotta has invented and patented, along with his laboratory co-inventors, transformative technologies in the fields of diagnostics, cancer molecular therapeutics, Laser Capture Microdissection, and proteomics (Reverse Phase Protein Microarrays, Biomarker Harvesting Nanoparticles, preservation chemistries for molecular analysis, and “protein painting” for drug target mapping) that have been used to make broad discoveries in cancer biology, and diagnostics, and therapeutics. The Laser Capture Microdissection prototype is in the Smithsonian Collection. He is a co-founder of Theranostics Health and Ceres Nanosciences. Dr. Liotta has more than 100 issued or allowed patents and more than 700 publications. He is an ISI highly cited investigator and the recipient of numerous awards for biomedical research including the 2015 Outstanding Virginia Faculty Award (SCHEV), the Flemming Award for Cancer Research, the Warner-Lambert Parke Davis Award, and the Surgeon General’s Medallion. He is Board Certified in Anatomic Pathology and is Medical Director of the GMU CAP/CLIA certified clinical proteomics Lab.
Dr. Emanuel F. Petricoin
Scientific Advisory Board Chairman
Dr. Emanuel F. Petricoin has been the Co-Director of the Center for Applied Proteomics and Molecular Medicine (CAPMM) at George Mason University since 2005, where he is a University Professor. The focus of the CAPMM is the invention and use of proteomics technologies for personalized therapy, molecular diagnostics and biomarker discovery. He is a co-founder of 4 life science companies in the nanotechnogy-diagnostic and precision medicine space. He has co-authored nearly 400 publications, and is a co-inventor on 40 filed and published patents. He has authored over 45 book chapters, is a Senior Editor for Cancer Epidemiology Biomarkers and Prevention and on the editorial board of JCO Precision Oncology, Nature Precision Oncology, Proteomics, Biomedical Microdevices, Proteomics-Clinical Applications, Proteomics-Protocols, Molecular, Carcinogenesis, Journal of Personalized Medicine and Dr. Petricoin is a founding member of the Human Proteomic Organization (HUPO). He has received numerous awards including the University Professorship at George Mason University, the NIH Director’s Award, FDA Distinguished Scientist Award, 2015 Innovator of the Year Award, GAP50 Top Virginia Entrepreneurs, Nifty 50 Award, American Society of Cytopathology Basic Research Award, the Roche Diagnostics/CLAS Distinguished Scientist Award and the Harvard University Leading Edge Award and is a Kentucky Colonel.
Virginia Espina, Ph.D.
Virginia (Ginny) Espina, PhD, is a Research Associate Professor at George Mason University in the Center for Applied Proteomics and Molecular Medicine. Dr. Espina is the technical director and manager of the CAP/CLIA accredited Clinical Proteomics laboratory. She received her BS in Medical Technology from Rochester Institute of Technology, a MS in Biotechnology from Johns Hopkins University, and a PhD in Biosciences from George Mason University. She has strong operations management, technical, and regulatory skills with over 20 years’ experience in clinical and academic research labs. Dr. Espina designs and performs basic/translational research studies and human clinical trials, which focus on elucidating potential therapeutic targets in the tissue microenvironment for cancer and infectious diseases. Since 2002, her translational research projects have resulted in 6 issued patents, in the areas of tissue preservation, mechanisms of development/treatment of premalignant lesions, and novel diagnostic technologies. Her work has led to the widespread adoption of reverse phase protein array and laser capture microdissection for personalized medicine. Dr. Espina is frequently an invited speaker at technology workshops and international conferences. Dr. Espina is on the editorial board of Molecular and Cellular Proteomic and serves as a peer reviewer for several journals. Dr. Espina is an author of more than 100 peer-reviewed publications and editor of Molecular Profiling in the Methods in Molecular Biology series. She is a member of the American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), American Thyroid Association (ATA), and American Society for Cell Biology (ASCB), American Society for Biochemistry and Molecular Biology (ASBMB), and American Society for Clinical Pathology (ASCP). Dr. Espina is a board certified Medical Technologist (ASCP).